Hepatitis Monthly

Published by: Kowsar

Enhancement of Immune Responses by Co-delivery of CCL19/MIP-3beta Chemokine Plasmid With HCV Core DNA/Protein Immunization

Christine Hartoonian 1 , 2 , Zargham Sepehrizadeh 1 , * , Mojtaba Tabatabai Yazdi 1 , Yong Suk Jang 3 , Lida Langroudi 2 , Parisa Amir Kalvanagh 2 , 4 , Babak Negahdari 4 , 5 , Ali Karami 6 , Massoumeh Ebtekar 4 and Kayhan Azadmanesh 2 , *
Authors Information
1 Department of Pharmaceutical Biotechnology and Biotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, IR Iran
2 Department of Virology, Pasteur Institute of Iran, Tehran, IR Iran
3 Departments of Molecular Biology and Bioactive Material Sciences, Institute for Molecular Biology and Genetics, Chonbuk National University, Jeonju, Korea
4 Department of Immunology, Faculty of Medical Sciences, Tarbiat Modaress University, Tehran, IR Iran
5 Department of Medical Biotechnology, School of Advanced Technologies, Tehran University of Medical Sciences, Tehran, IR Iran
6 Department of Research Center of Molecular Biology, Baqyiatallah University of Medical Sciences, Tehran, IR Iran
Corresponding Authors:
Article information
  • Hepatitis Monthly: March 01, 2014, 14 (3); e14611
  • Published Online: March 1, 2014
  • Article Type: Research Article
  • Received: September 22, 2013
  • Revised: December 1, 2013
  • Accepted: December 5, 2013
  • DOI: 10.5812/hepatmon.14611

To Cite: Hartoonian C, Sepehrizadeh Z, Tabatabai Yazdi M, Jang Y S, Langroudi L, et al. Enhancement of Immune Responses by Co-delivery of CCL19/MIP-3beta Chemokine Plasmid With HCV Core DNA/Protein Immunization, Hepat Mon. 2014 ; 14(3):e14611. doi: 10.5812/hepatmon.14611.

Abstract
Copyright © 2014, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Kim CW, Chang KM. Hepatitis C virus: virology and life cycle. Clin Mol Hepatol. 2013; 19(1): 17-25
  • 2. Pavio N, Lai MM. The hepatitis C virus persistence: how to evade the immune system? J Biosci. 2003; 28(3): 287-304[PubMed]
  • 3. Gellad ZF, Reed SD, Muir AJ. Economic evaluation of direct-acting antiviral therapy in chronic hepatitis C. Antivir Ther. 2012; 17(6 Pt B): 1189-99[DOI][PubMed]
  • 4. Esteban R, Buti M. Triple therapy with boceprevir or telaprevir for treatment naive HCV patients. Best Pract Res Clin Gastroenterol. 2012; 26(4): 445-53[DOI][PubMed]
  • 5. Kozielewicz D, Halota W, Dybowska D. [Efficacy of triple therapy in patients with chronic hepatitis C not treated and patients previously treated ineffectively]. Przegl Epidemiol. 2012; 66(1): 49-54[PubMed]
  • 6. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med. 2000; 132(4): 296-305[PubMed]
  • 7. Liao G, Wang Y, Chang J, Bian T, Tan W, Sun M, et al. Hepatitis B virus precore protein augments genetic immunizations of the truncated hepatitis C virus core in BALB/c mice. Hepatology. 2008; 47(1): 25-34[DOI][PubMed]
  • 8. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989; 244(4902): 359-62[PubMed]
  • 9. Lowe DB, Shearer MH, Kennedy RC. DNA vaccines: successes and limitations in cancer and infectious disease. J Cell Biochem. 2006; 98(2): 235-42[DOI][PubMed]
  • 10. Barouch DH, Letvin NL, Seder RA. The role of cytokine DNAs as vaccine adjuvants for optimizing cellular immune responses. Immunol Rev. 2004; 202: 266-74[DOI][PubMed]
  • 11. Tsen SW, Paik AH, Hung CF, Wu TC. Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells. Expert Rev Vaccines. 2007; 6(2): 227-39[DOI][PubMed]
  • 12. Ngo VN, Tang HL, Cyster JG. Epstein-Barr virus-induced molecule 1 ligand chemokine is expressed by dendritic cells in lymphoid tissues and strongly attracts naive T cells and activated B cells. J Exp Med. 1998; 188(1): 181-91[PubMed]
  • 13. Forster R, Davalos-Misslitz AC, Rot A. CCR7 and its ligands: balancing immunity and tolerance. Nat Rev Immunol. 2008; 8(5): 362-71[DOI][PubMed]
  • 14. Riol-Blanco L, Sanchez-Sanchez N, Torres A, Tejedor A, Narumiya S, Corbi AL, et al. The chemokine receptor CCR7 activates in dendritic cells two signaling modules that independently regulate chemotaxis and migratory speed. J Immunol. 2005; 174(7): 4070-80[PubMed]
  • 15. Kaiser A, Donnadieu E, Abastado JP, Trautmann A, Nardin A. CC chemokine ligand 19 secreted by mature dendritic cells increases naive T cell scanning behavior and their response to rare cognate antigen. J Immunol. 2005; 175(4): 2349-56[PubMed]
  • 16. Westermann J, Nguyen-Hoai T, Baldenhofer G, Hopken UE, Lipp M, Dorken B, et al. CCL19 (ELC) as an adjuvant for DNA vaccination: induction of a TH1-type T-cell response and enhancement of antitumor immunity. Cancer Gene Ther. 2007; 14(6): 523-32[DOI][PubMed]
  • 17. Eo SK, Lee S, Kumaraguru U, Rouse BT. Immunopotentiation of DNA vaccine against herpes simplex virus via co-delivery of plasmid DNA expressing CCR7 ligands. Vaccine. 2001; 19(32): 4685-93[PubMed]
  • 18. Han YW, Aleyas AG, George JA, Kim SJ, Kim HK, Yoo DJ, et al. Genetic co-transfer of CCR7 ligands enhances immunity and prolongs survival against virulent challenge of pseudorabies virus. Immunol Cell Biol. 2009; 87(1): 91-9[DOI][PubMed]
  • 19. Juarez V, Pasolli HA, Hellwig A, Garbi N, Arregui AC. Virus-Like Particles Harboring CCL19, IL-2 and HPV16 E7 Elicit Protective T Cell Responses in HLA-A2 Transgenic Mice. Open Virol J. 2012; 6: 270-6[DOI][PubMed]
  • 20. Hartoonian C, Ebtekar M, Soleimanjahi H, Karami A, Mahdavi M, Rastgoo N, et al. Effect of immunological adjuvants: GM-CSF (granulocyte-monocyte colony stimulating factor) and IL-23 (interleukin-23) on immune responses generated against hepatitis C virus core DNA vaccine. Cytokine. 2009; 46(1): 43-50[DOI][PubMed]
  • 21. Yang J, Wang S, Zhao G, Sun B. Effect of chemokine receptors CCR7 on disseminated behavior of human T cell lymphoma: clinical and experimental study. J Exp Clin Cancer Res. 2011; 30: 51[DOI][PubMed]
  • 22. Roohvand F, Aghasadeghi MR, Sadat SM, Budkowska A, Khabiri AR. HCV core protein immunization with Montanide/CpG elicits strong Th1/Th2 and long-lived CTL responses. Biochem Biophys Res Commun. 2007; 354(3): 641-9[DOI][PubMed]
  • 23. Lohr HF, Schmitz D, Arenz M, Weyer S, Gerken G, Meyer zum Buschenfelde KH. The viral clearance in interferon-treated chronic hepatitis C is associated with increased cytotoxic T cell frequencies. J Hepatol. 1999; 31(3): 407-15[PubMed]
  • 24. Hartoonian C, Ebtekar M, Soleimanjahi H, Karami A, Mahdavi M, Rastgoo N, et al. Effect of immunological adjuvants: GM-CSF (granulocyte-monocyte colony stimulating factor) and IL-23 (interleukin-23) on immune responses generated against hepatitis C virus core DNA vaccine. Cytokine. 2009; 46(1): 43-50
  • 25. Roohvand F, Kossari N. Advances in hepatitis C virus vaccines, Part one: Advances in basic knowledge for hepatitis C virus vaccine design. Expert Opin Ther Pat. 2011; 21(12): 1811-30[DOI][PubMed]
  • 26. Roohvand F, Kossari N. Advances in hepatitis C virus vaccines, part two: advances in hepatitis C virus vaccine formulations and modalities. Expert Opin Ther Pat. 2012; 22(4): 391-415[DOI][PubMed]
  • 27. Mohit E, Rafati S. Chemokine-based immunotherapy: delivery systems and combination therapies. Immunotherapy. 2012; 4(8): 807-40[DOI][PubMed]
  • 28. Hu K, Luo S, Tong L, Huang X, Jin W, Huang W, et al. CCL19 and CCL28 Augment Mucosal and Systemic Immune Responses to HIV-1 gp140 by Mobilizing Responsive Immunocytes into Secondary Lymph Nodes and Mucosal Tissue. J Immunol. 2013; 191(4): 1935-47[DOI][PubMed]
  • 29. Foged C. Subunit vaccines of the future: the need for safe, customized and optimized particulate delivery systems. Ther Deliv. 2011; 2(8): 1057-77
  • 30. Yazdanian MMA, Mahdavi M, Sadat M, Motevali F, Vahabpour R, Khanhmad H, Siadat SD, Aghasadeghi MR, Roohvand F. Immunization of Mice by BCG Formulated HCV Core Protein Elicited Higher Th1-Oriented Responses Compared to Pluronic-F127 Copolymer. Hepatitis Monthly. 2013; 13(10)[DOI]
  • 31. Baekkevold ES, Yamanaka T, Palframan RT, Carlsen HS, Reinholt FP, von Andrian UH, et al. The CCR7 ligand elc (CCL19) is transcytosed in high endothelial venules and mediates T cell recruitment. J Exp Med. 2001; 193(9): 1105-12[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments